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ORIGINAL ARTICLE
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Summary. Background: In comparison to the classical iso-
forms of protein kinase C (PKC), the novel isoforms are
thought to play minor or inhibitory roles in the regulation
of platelet activation and thrombosis. Objectives: To mea-
sure the levels of PKCh and PKCe and to investigate the
phenotype of mice deﬁcient in both novel PKC iso-
forms. Methods: Tail bleeding and platelet activation assays
were monitored in mice and platelets from mice deﬁcient in
both PKCh and PKCe. Results: PKCe plays a minor role in
supporting aggregation and secretion following stimulation of
the collagen receptor GPVI in mouse platelets but has
no apparent role in spreading on ﬁbrinogen. PKCh, in
contrast, plays a minor role in supporting adhesion and
ﬁlopodial generation on ﬁbrinogen but has no apparent role
in aggregation and secretion induced by GPVI despite being
expressed at over 10 times the level of PKCe. Platelets
deﬁcient in both novel isoforms have a similar pattern of
aggregation downstream of GPVI and spreading on ﬁbrin-
ogen as the single null mutants. Strikingly, a marked
reduction in aggregation on collagen under arteriolar shear
conditions is observed in blood from the double but not
single-deﬁcient mice along with a signiﬁcant increase in
tail bleeding. Conclusions: These results reveal a greater
than additive role for PKCh and PKCe in supporting
platelet activation under shear conditions and demonstrate
that, in combination, the two novel PKCs support platelet
activation.
Keywords: aggregation, bleeding times, collagen, ﬁbrinogen,
hemostasis, protein kinase C.
Introduction
Following damage to the blood vessel wall, components of the
subendothelial matrix such as collagen become exposed and
activate platelets circulating in the blood. Platelet activation
involves granule secretion, activation of the major platelet
integrin aIIbb3, actin rearrangements and generation of
thrombin, which ampliﬁes platelet activation, thrombus for-
mation and hemostasis.
The protein kinase C (PKC) serine/threonine kinase family
plays a critical role in the regulation of several processes
involved in platelet activation. Broad spectrum inhibition of all
PKC family members blocks platelet responses to most
agonists, including collagen and thrombin [1–3]. The PKC
superfamily consists of 10 isoforms subdivided into classical (a,
bI, bII, c), novel (d, e,g, h) and atypical (n, i/k) isoforms on the
basis of their domain structure and sensitivity to 1,2-diacyl-
glycerol and Ca2+. Robust expression of several isoforms has
been reported in human (a, b, d, h) and mouse (a, b, e, d, h)
platelets, with evidence of expression of additional isoforms. In
contrast, there are conﬂicting reports on expression of PKCe in
human platelets [4–7], although a recent study using an in-
house antibody has demonstrated robust expression [8].
The role of individual isoforms in platelet activation has been
investigated using isoform-speciﬁc inhibitors and mice deﬁcient
in single isoforms [4–7,9–19]. This has led to the conclusion that
the classical isoforms play positive roles in platelet activation,
with PKCa playing the predominant role, supported by PKCb,
while the novel isoforms play minor or inhibitory roles [10].
There is, however, a need for caution in this generalized
overview as there is increasing evidence that individual
isoforms of classical and novel PKCs have agonist-speciﬁc
roles.
This is illustrated by PKCe, which supports activation of
mouse platelets by GPVI through serine phosphorylation of
the FcR c-chain, leading to increased binding activation of the
tyrosine kinase Syk [6]. In contrast, PKCe has been shown to
play a role in the negative regulation of G protein coupled
receptor signaling, in particular in the regulation of ADP-
induced platelet dense granule secretion [8,20]. In comparison,
the novel isoform PKCh is required for aIIbb3-mediated
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adhesion and ﬁlopodial generation on ﬁbrinogen [14,18] but
has only a minor role downstream of GPVI and PAR
receptors, with both stimulatory and inhibitory results
observed, possibly reﬂecting subtle changes in experimental
conditions [7,10,14,15,18,21,22]. The role of PKCh in platelet
aggregation under ﬂow conditions is unclear, with a stimula-
tory [7,15], inhibitory [10,14] and or no signiﬁcant role [18]
being reported, again most likely reﬂecting differences in the
experimental conditions.
In the present study, we have investigated platelet activation
in mice deﬁcient in the two novel isoforms, PKCh and PKCe.
Although mice deﬁcient in multiple classical isoforms have
been described [23], this is the ﬁrst report of mice lacking two
novel isoforms. Mice deﬁcient in PKCh and PKCe show a
marked reduction in aggregation on collagen at arteriolar shear
and exhibit a signiﬁcant increase in tail bleeding in vivo relative
to wild-type (WT) mice or mice deﬁcient in one novel isoform.
These results reveal a combined positive role of PKCe and
PKCh in supporting platelet activation.
Materials and methods
PKCh)/)/e)/)mice were bred from PKCh)/)/e+/) parents on a
B6 background and results compared with age-matched wild-
type background C57/BL6 and litter-matched PKCh)/)/e+/+
controls. PKCe)/) mouse platelets were compared with wild-
type littermate C57/BL6 controls. Animals were bred and
blood removed under an approved Home Ofﬁce Licence (Ref:
PPL 30/2721). P-PACK (D-Phe-Pro-Arg-chloromethylketone,
HCl) was from Merck Biosciences Ltd (Nottingham, UK).
Actin antibody was from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA). PKC antibodies were from BD
Biosciences (Oxford, UK), except for PKCa, which was
purchased from Cell Signalling Technology (Beverly, MA,
USA). Other reagents were from Sigma (Poole, UK) or as
previously described [6].
Washed platelet preparation
Mouse bloodwas drawn either by cardiac puncture or from the
vena cavae of terminally CO2-narcosed mice, anesthetized with
gaseous isoﬂuorane. Blood was taken into 100 lL ACD and
200 lL modiﬁed Tyrodes-Hepes buffer (138 mM NaCl,
2.7 mM KCl, 1 mM MgCl2, 3 mM NaH2PO4, 5 mM glucose
and 10 mMHEPES) pH 7.3 and centrifuged at 200 g for 6 min;
separation from PRP was by spinning at 1000 g for 6 min.
Platelets were adjusted to ensure a count of at least 108
platelets mL)1. Human platelets were isolated as previously
described [6] with ethical approval from the Oxford Research
Ethics Council (reference number 08/H0605/123).
Quantification of the PKC isoform levels
The PKC isoforms were quantiﬁed using washed platelet
samples from three wild-type mice and ﬁve human donors
using antibodies speciﬁc for each isoform. The relative
expression of levels of each PKC isoform was determined
using quantitative western blotting [24–26]. A range of known
concentrations of reference samples, GST-tagged forms of each
human PKC isoform (purchased from Enzo Life Sciences,
Exeter, UK), were subjected to western blotting and bands
were quantiﬁed using ECL in combination with the Biorad
GelDoc system. Corresponding recognition regions are at least
97% conserved between human and mouse isoforms. Expres-
sion levels were calculated by comparing the level of PKC
isoforms present in platelet samples with those of the reference
samples. The level of expression of PKC isoform per platelet
was calculated both as the number ofmolecules per platelet and
as a concentration.
Aggregometry and ATP release
Aggregation and ATP secretion were monitored following
stimulation by the required agonist as previously described
using washed platelets [6].
Flow cytometry
Expression of cell surface glycoproteins was measured by ﬂow
cytometry [6].
Spreading on fibrinogen
Washed platelets (2 · 107 mL)1) were exposed to ﬁbrinogen-
coated coverslips (100 lg mL)1) and adherent platelets were
imaged using phase contrast microscopy [27].
Aggregate formation on collagen under shear
Anticoagulated (heparin [5 IU mL)1] and PPACK [40 lM]),
whole blood was perfused through collagen-coated capillaries
at a shear rate of 1000 s)1. Thrombus formation was imaged
using phase-contrast microscopy and expressed as the percent-
age of surface area covered by platelets. Capillary contents
were lysed and levels of adherent platelets assessed by western
blotting for actin [6].
Tail bleeding
Tail bleeding experiments were performed on 20–35 gmale and
female mice, anesthetized with isoﬂuorane and injected with
buprenorphine intraperitoneally. The terminal 3 mm of tail
was removed using a sharp razor blade and blood collected.
Mice were allowed to bleed until they lost either 15% blood
volume or for a maximum of 20 min. Data are presented as
ratio of amount of blood loss (mg)/mouse weight (g) and rate
of blood loss (mg min)1).
Statistical analysis
For all results n ‡ 3 for WT, PKCh)/) and PKCh)/)/e)/)mice.
Statistical analyses were carried out on data using unpaired,
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two-tailed Students t-test, and P < 0.05 was considered
statistically signiﬁcant. Values are expressed as mean ± SEM.
Results
PKCh)/)/e)/) mouse platelets exhibit normal expression of
the other PKC isoforms
Quantiﬁcation of the levels of PKC isoforms in both human
and mouse platelets revealed that expression varies over more
than two orders of magnitude. PKCh is the most highly
expressed isoform in both species, even though its role has
proven difﬁcult to deﬁne. In comparison, the level of PKCe
expression in mouse platelets is < 5% of that of PKCh
(Fig. S1). The level of PKCe in human platelets, however, is
unclear as we were not able to detect expression using
commercially available antibodies, although a recent study
using an in-house antibody has reported robust expression [8].
To determine whether any functional redundancy exists
between the novel isoforms PKCh and PKCe, mice deﬁcient in
both isoforms were bred and their platelet activity monitored in
comparison toPKCh)/), PKCe)/) andwild-type controls.Mice
deﬁcient in both PKCh and PKCe were indistinguishable from
littermate controls for up to 30 weeks and had similar platelet
counts and platelet size (data not shown). The expression of the
major PKC isoforms was compared in WT, PKCh)/) and
PKCh)/)/e)/) washed platelet lysates (Fig. 1). As expected, no
expression of PKCh, and neither PKCh or PKCe, could be
detected in platelets puriﬁed from PKCh)/) and PKCh)/)/e)/)
mice, respectively. There was also no signiﬁcant changes in
expression of other PKC isoforms in PKCh)/)/e)/) platelets
relative to PKCh)/) or WT platelets (Fig. 1). We have also
previously reported thatexpressionofotherPKCisoforms isnot
altered inmice deﬁcient solely inPKCe [6]. ExpressionofGPVI,
GPIb and aIIbb3 were also similar in double-deﬁcient platelets
to those in controls (Fig. S2). Similar observations have been
reported for the single nulls (Fig. S2) [6,7,14,15,18]. This
indicates that any functional differences between the PKCh)/)/
PKCe)/) platelets relative to PKCh)/) and PKCe)/) or WT
platelets are not due to altered expressionof surface receptors or
other PKC isoforms.
Distinct roles for PKCh and PKCe in platelet activation
We have previously reported a mild defect in aggregation and
dense granule secretion in PKCe)/) mouse platelets to the
GPVI-speciﬁc agonist collagen-related-peptide (CRP) [6]. In
contrast, we found no signiﬁcant difference in aggregation or
dense granule secretion in PKCh)/) mouse platelets relative to
controls in response to concentrations of CRP that induce
partial and full aggregation (Fig. 2A). Washed platelets from
PKCh)/)/e)/) mice exhibit a similar delay in onset and
reduction of aggregation and ATP secretion in response to
low and high concentrations of CRP as that previously
reported in PKCe)/) mouse platelets (Fig. 2B) [8]). Direct
comparison of PKCh)/)/e)/) and PKCe)/) mouse platelets
conﬁrmed a similar defect in CRP-induced responses (Fig. 2C).
Thus, PKCh does not play a critical role in GPVI signaling
even in the absence of the novel isoform PKCe. No signiﬁcant
difference was observed in the rate or extent of aggregation or
dense granule secretion in PKCh)/) or PKCh)/)/e)/) platelets
relative to WT mice in response to threshold concentrations of
thrombin (Fig. S3).
As we have previously shown [6], adhesion and ﬁlopodial
generation on ﬁbrinogen are not altered in the absence of PKCe
(Fig. 3). In contrast, a reduction in adhesion and ﬁlopodia
generation on a ﬁbrinogen-coated surface was observed in
PKCh)/) platelets in agreement with earlier studies [14,18]. A
similar defect was also observed in PKCh)/)/e)/) platelets
(Fig. 4), whichwas indistinguishable from that seen in PKCh)/)
platelets. Thus, PKCe does not play a critical role in ﬁbrinogen
signaling even in the absence of the novel isoform PKCh.
Platelet activation is reinforcedby the feedbackagonistsADP
and thromboxane A2. Aggregation induced by a low concen-
tration of the thromboxane agonist mimetic, U46619, was not
altered in platelets deﬁcient in either PKCh or PKCe or in the
absenceof bothnovel isoforms (datanot shown).Weandothers
have previously reported that secretion in response to ADP is
potentiated in the absence of PKCe, although this did not
translate into a change in aggregation [6,8,20]. This result was
conﬁrmed in the present study, although interestingly potenti-
ationwas not observed in the absence of both PKCe and PKCh
(Fig. 4). This highlights a positive role for PKCh in the
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Fig. 2. The role of PKCh and PKCe in GPVI-induced platelet activation. Mouse washed platelets from (A) PKCh)/)mice or wild-type littermate controls
(WT) and (B) PKCh)/)/e)/) mice or PKCh)/) littermate controls were stimulated with low (0.3 lg mL)1) or just maximal (1 lg mL)1) CRP. (C) Mouse
washed platelets from PKCh)/)/e)/), PKCe)/) or wild-type (WT) mice were stimulated with low (1 lg mL)1) or high (3 lg mL)1) CRP [CRP potency is
batch dependent, and so concentrations can vary to induce the same response, therefore although they induce similar submaximal and near maximal
responses, the concentrations used in (C) are diﬀerent to those in (A) and (B)]. Aggregation wasmeasured by optical aggregometry. Dense granule secretion
was measured by monitoring ATP secretion using luminometry. (i) Traces representative of n = 3 are shown. (ii) Results are average + SEM for n = 3
(A and B), n ‡ 2 (C). *P < 0.05 in comparison to controls.
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regulation of ADP-induced dense granule secretion, which
opposes that of PKCe.
These results suggest isoform-speciﬁc rather than redundant
roles for the two novel PKC isoforms, PKCh and PKCe, in
supporting platelet aggregation, secretion and adhesion and
ﬁlopodial generation.
PKCh)/)/e)/) platelets show reduced aggregation under shear
and mice show bleeding defects
Our observations suggest isoform-speciﬁc rather than redun-
dant roles for PKCh and PKCe. To determine whether loss of
both isoforms had a cumulative effect on platelet function,
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platelet aggregation and thrombus formation under arteriolar
ﬂow rates were investigated by ﬂowing whole blood over
immobilized collagen at an arteriolar shear rate of 1000 s)1. As
we have previously shown, PKCe)/) platelets show no
signiﬁcant difference in aggregate and thrombus formation
under these conditions (Fig. 5A) [6]. There was also no
signiﬁcant difference in aggregation on collagen in PKCh)/)
blood under these conditions (Fig. 5A). In contrast, a marked
reduction in platelet aggregation on collagen was observed at a
shear rate of 1000 s)1 in PKCh)/)/PKCe)/) platelets (Fig. 5A),
with platelets forming small unstable aggregates. This result
demonstrates that at high shear platelet aggregation on
collagen is regulated by the combined action of PKCh and
PKCe.
We further investigated whether PKCh and PKCe are
required for hemostasis in vivo using a tail bleeding assay. There
was no signiﬁcant increase in bleeding times in the single
isoform null mice in comparison to WT controls. In contrast,
there was amarked increase in blood lost and time to occlusion
in the double-deﬁcient mice (Fig. 5B). This reveals that the two
novel isoforms also work in combination to support hemosta-
sis.
Discussion
It has been proposed that the classical isoforms PKCa and
PKCb play the dominant positive roles in the regulation of
platelet activation and thrombus formation, whilst the novel
isoforms are thought to play comparatively minor or in some
cases negative regulatory roles [9,10]. In the present study,
however, we show that the combined loss of the novel isoforms
PKCe and PKCh results in a marked defect in aggregation
under ﬂow conditions and a marked increase in tail bleeding,
revealing a combined net positive role for the two novel
isoforms in hemostasis, which may reﬂect their individual roles
in platelet activation by collagen and ﬁbrinogen, respectively.
PKCh is the most highly expressed PKC isoform in both
human and mouse platelets. Surprisingly, the high level
expression of PKCh is not associated with a major change in
GPVI and PAR4 receptor signaling in mouse platelets
[7,10,14,15,18,21,22], a result that has been conﬁrmed in the
present study. Differences with regard to PKCh function are
most likely due to minor changes in experimental design and
the relatively mild role of the novel PKC isoform in platelet
activation downstream of GPVI and PAR. On the other hand,
PKCh regulates adhesion and ﬁlopodia formation on ﬁbrin-
ogen [14,18], although this is not associated with altered
aggregation on collagen at an arteriolar rate of shear (present
study) or to a change in tail bleeding time [18]. In comparison,
PKCe is expressed at < 5% of the level of PKCh in mouse
platelets and the variable reports of its presence in human
platelets are consistent with a low level expression (see
Introduction). We have shown that PKCe plays a key role in
supporting platelet activation by GPVI [6], as well as secretion
(but not aggregation) by ADP in mouse platelets [20].
The use of mice deﬁcient in both PKCe and PKCh enables
the net contribution of the two isoforms to be studied. The
in vitro studies reveal that the isoform-speciﬁc functions of the
two novel PKCs are carried over to the double-deﬁcient
platelets, with the only departure being the loss of the increased
secretion to ADP in the PKCe-null platelets, suggesting that
PKCh opposes this response. Nevertheless, despite the rela-
50
40
30
20
SA
 c
ov
e
ra
ge
 %
10
0
6
0.20
0.15
0.10
0.00
0.05
*
*
*
5
4
3
2
1
0
Bl
oo
d 
we
ig
ht
 (m
g)/
To
ta
l w
e
ig
ht
 (g
)
R
at
e 
of
 b
lo
o
d 
lo
ss
(m
g s
ec
–
1 )
WT
P < 0.0001
PKCθ–/–PKCε–/– PKCθ–/–ε–/–
WT PKCθ–/–PKCε–/– PKCθ–/–ε–/– WT PKCθ–/–PKCε–/– PKCθ–/–ε–/–
A
B i ii
Fig. 5. Thrombus formation in PKCh)/)/e)/)mice. (A) Heparin/PPACK-anticoagulated blood fromWT, PKCe)/), PKCh)/) or PKCh)/)/e)/)mice was
passed over collagen (shear rate 1000 s)1). Surface area coverage with thrombi was calculated using three separate images per mouse, mean ± SEM. (B)
Tail bleeding as determined by blood lost in 20 min following removal of the terminal 3 mmof the tail; data presented as (i) a ratio of mouse weight and (ii)
rate of blood loss (n = 10 for WT, six for PKCe)/), 10 for PKCh)/), and six for PKCh)/)/e)/)). *P < 0.05 in comparison to WT controls.
1892 A. J. Unsworth et al
 2012 International Society on Thrombosis and Haemostasis
tively minor phenotype in response to individual agonists, the
present study demonstrates a marked reduction in aggregation
on collagen under arteriolar ﬂow rates and signiﬁcant increase
in tail bleeding in the combined absence of PKCh and PKCe. It
is already known that the two classical isoforms of PKC, PKCa
and PKCb, play a major role in supporting platelet activation
under static and ﬂow conditions [10,12]. The observation of a
signiﬁcant defect in aggregation on collagen at an arteriolar
rate of shear and in hemostasis (tail bleeding assay) in the
double-deﬁcient mice demonstrates that, in combination,
PKCe and PKCh also contribute to activation as a conse-
quence of distinct roles in platelet activation by GPVI and
integrin aIIbb3, respectively [10,12]. Thus both classical and
novel PKC isoforms are required for hemostasis in the
arteriolar system.
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